Moderna is the only company in its peer group burning cash at an alarming rate. Click here to read more about MRNA stock and ...

As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...

US mRNA specialist Moderna demonstrated substantial R&D investment and progress in the UK, two years since signing its ...

While some of the initial zeal around localized vaccine production in Africa has waned since the height of the COVID-19 pandemic, efforts to bolster the continent’s immunization autonomy—especially | ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

With only one commercial product – the COVID-19 vaccine – Moderna faces pressure to diversify its pipeline rapidly. As the company invests heavily in expanding its non-COVID mRNA vaccine ...

The patent has also been contested by Sanofi, which was also developing an mRNA-based COVID-19 vaccine ... led to a traditional private commercial model. Moderna and Pfizer/BioNTech have both ...

Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...

O n a freezing night in January, several hundred people came to Boston’s Museum of Science for a town hall-style discussion ...